<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03793712</url>
  </required_header>
  <id_info>
    <org_study_id>17972A</org_study_id>
    <nct_id>NCT03793712</nct_id>
  </id_info>
  <brief_title>Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia</brief_title>
  <official_title>Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-flexible-dose Study of Lu AF11167 for the Treatment of Persistent Prominent Negative Symptoms in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms&#xD;
      in patients with schizophrenia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy based on interim analysis&#xD;
  </why_stopped>
  <start_date type="Actual">December 27, 2018</start_date>
  <completion_date type="Actual">September 3, 2020</completion_date>
  <primary_completion_date type="Actual">August 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Negative Symptom Scale (BNSS) total score</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <description>The BNSS is a brief clinician rating scale, intended to measure negative symptoms. It consists of 13 items organized into 6 subscales: anhedonia, distress, asociality, avolition, blunted affect and alogia. The items score the impairment. Items 1 to 4 are rated from 0 (Normal) to 6 (Extremely severe) and items 5 to 13 are rated from 0 (No impairment) to 6 (Severe deficit). The BNSS total score is calculated by summing the 13 individual items; subscale scores are calculated by summing the individual items within each subscale. Users of the BNSS should have training in psychiatric interview techniques and have clinical experience working with patients with schizophrenia and related psychotic disorders. The BNSS total scores ranges from 0 to 78.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Personal and Social Performance (PSP) score</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <description>The PSP is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. The PSP consists of 4 items: socially useful activities (including work and study), personal and social relationships, self-care, and disturbing and aggressive behaviours. The 4 items are assessed on a 6-point scale, from absent to very severe. Based on these assessments and their combination, individual scores are converted into a global score ranging from 1 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale (PANSS) total score</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <description>The PANSS is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS includes 3 sub-scales and 30 items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PANSS Marder Negative Symptom Factor score: negative symptoms</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <description>The PANSS is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS includes 3 sub-scales and 30 items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PANSS Negative subscale score</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <description>The PANSS is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS includes 3 sub-scales and 30 items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression - Schizophrenia (CGI-SCH-S) negative symptoms score</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <description>The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive and depressive) and the overall severity of the disorder. The CGI-SCH-S severity of illness category symptoms and overall severity are rated on a 7-point scale ranging from 1 (normal - not ill) to 7 (Among the most severely ill). For the first four ratings (positive, negative, depressive, and cognitive symptoms), the assessment should focus on the severity of symptoms only. Additionally, for 'overall severity' rating, both severity of symptoms and interference with functioning should be considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Schizophrenia (CGI-SCH-DC) negative symptoms score</measure>
    <time_frame>at Week 12</time_frame>
    <description>The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive and depressive) and the overall severity of the disorder. In the CGI-SCH-DC degree of change category symptoms and overall severity are rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Each single rating (conditions of severity and degree of improvement) and overall ratings of severity and improvement are scored independently and no total score is derived.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-SCH-DC negative symptoms response</measure>
    <time_frame>at Week 12</time_frame>
    <description>The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive and depressive) and the overall severity of the disorder. In the CGI-SCH-DC degree of change category symptoms and overall severity are rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Each single rating (conditions of severity and degree of improvement) and overall ratings of severity and improvement are scored independently and no total score is derived. Response defined as CGI-SCH-DC negative symptoms = 1 or 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNSS response</measure>
    <time_frame>at Week 12</time_frame>
    <description>The BNSS is a brief clinician rating scale, intended to measure negative symptoms. It consists of 13 items organized into 6 subscales: anhedonia, distress, asociality, avolition, blunted affect and alogia. The items score the impairment. Items 1 to 4 are rated from 0 (Normal) to 6 (Extremely severe) and items 5 to 13 are rated from 0 (No impairment) to 6 (Severe deficit). The BNSS total score is calculated by summing the 13 individual items; subscale scores are calculated by summing the individual items within each subscale. Users of the BNSS should have training in psychiatric interview techniques and have clinical experience working with patients with schizophrenia and related psychotic disorders. The BNSS total scores ranges from 0 to 78. Response criteria defined as 20,30 or 40% decrease in BNSS total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PANSS -Positive subscale score</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <description>The PANSS is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS includes 3 sub-scales and 30 items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression - Schizophrenia (CGI-SCH-S) severity of illness overall severity score</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <description>The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive and depressive) and the overall severity of the disorder. The CGI-SCH-S severity of illness category symptoms and overall severity are rated on a 7-point scale ranging from 1 (normal - not ill) to 7 (Among the most severely ill). For the first four ratings (positive, negative, depressive, and cognitive symptoms), the assessment should focus on the severity of symptoms only. Additionally, for 'overall severity' rating, both severity of symptoms and interference with functioning should be considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Schizophrenia (CGI-SCH-DC) degree of change in overall severity score</measure>
    <time_frame>at Week 12</time_frame>
    <description>The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive and depressive) and the overall severity of the disorder. In the CGI-SCH-DC degree of change category symptoms and overall severity are rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Each single rating (conditions of severity and degree of improvement) and overall ratings of severity and improvement are scored independently and no total score is derived.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Calgary Depression Scale for Schizophrenia (CDSS) total score</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <description>The CDSS is a 9-item clinician rated scale specifically developed for the assessment of depression in patients with schizophrenia. The items on the CDSS are all typical depressive symptoms and do not appear to overlap with the negative symptoms of schizophrenia. All items are rated on a 4-point scale from 0 (absent) to 3 (severe)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Lu AF11167 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AF11167 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF11167 (1-2 mg/day)</intervention_name>
    <description>Fixed-flexible oral dose, tablets. Once daily. 12 weeks.</description>
    <arm_group_label>Lu AF11167 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF11167 (3-4 mg/day)</intervention_name>
    <description>Fixed-flexible oral dose, tablets. Once daily. 12 weeks.</description>
    <arm_group_label>Lu AF11167 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral dose, tablets. Once daily. 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  The patient has schizophrenia, diagnosed according to DSM-5® as confirmed by the&#xD;
             Mini-International Neuropsychiatric Interview for Schizophrenia and Psychotic&#xD;
             Disorders Studies (MINI-Schz).&#xD;
&#xD;
          -  The patient has been known to the site or investigator and treated by the site or&#xD;
             investigator for at least the last 6 months prior to Screening Visit 1.&#xD;
&#xD;
          -  The patient has suffered from persistent prominent negative symptoms for the last 6&#xD;
             months prior to the Screening Visit 1, in the opinion of the investigator and recorded&#xD;
             in medical records.&#xD;
&#xD;
          -  The patient has been treated for schizophrenia with stable doses of an oral&#xD;
             antipsychotic within the approved dose range and without any dose increase during the&#xD;
             last 6 months prior to Screening Visit 1 (dose reductions are acceptable). Combination&#xD;
             therapy of two antipsychotics is only allowed with the written approval of the Medical&#xD;
             Monitor in cases where the second antipsychotic is a low-potency first generation&#xD;
             antipsychotic drug (e.g., chlorpromazine, promazine or chlorprothixene at low doses)&#xD;
             or quetiapine at a dose of ≤150 mg, given in the evening for sleep problems and where&#xD;
             both can be discontinued during the washout phase without endangering the patient's&#xD;
             safety. Both antipsychotics will be withdrawn during the washout phase and need to be&#xD;
             discontinued before Screening Visit 2. Combination therapy of more than 2&#xD;
             antipsychotic medications is not allowed during the previous 6 months prior to&#xD;
             Screening Visit 1.&#xD;
&#xD;
          -  The patient has had no psychiatric admissions/hospitalization due to a clinical&#xD;
             deterioration during the last 6 months prior to Screening Visit 1, this excludes&#xD;
             ambulatory visits to ask for advice from the psychiatry team.Patients hospitalized&#xD;
             during the last 6 months for social reasons only or patients who are currently&#xD;
             hospitalized for social reasons can be included with the Medical Monitor's approval.&#xD;
&#xD;
          -  The patient is in a clinically stable phase of schizophrenia and has not more than&#xD;
             moderate severity on relevant positive symptoms, that is a score of ≤4 (moderate) out&#xD;
             of score of 7 on each of the following PANSS items: Delusions (P1), Hallucinatory&#xD;
             behaviour (P3), Suspiciousness / persecution (P6), Uncooperativeness (G8), Unusual&#xD;
             thought content (G9) at Screening Visit 1, Washout Visit(s), Screening Visit 2, and&#xD;
             Baseline Visit and a score ≤5 on Conceptual disorganization (P2).&#xD;
&#xD;
          -  The patient currently has no clinically significant acute extrapyramidal side effects&#xD;
             (acute EPS) or tardive dyskinesia (TD) based upon the protocol-specified clinical&#xD;
             examination.&#xD;
&#xD;
          -  The patient has prominent negative symptoms as demonstrated by a PANSS Marder Negative&#xD;
             Symptom Factor Score (NSFS) ≥20 at Screening Visit 1, Washout Visit(s) and Screening&#xD;
             Visit 2. NSFS is the sum of scores of the following PANSS items: Blunted affect (N1),&#xD;
             Emotional withdrawal (N2), Poor rapport (N3), Passive/apathetic social withdrawal&#xD;
             (N4), Lack of spontaneity &amp; flow of conversation (N6), Motor retardation (G7) and&#xD;
             Active social avoidance (G16).&#xD;
&#xD;
          -  The patient has a Clinical Global Impression-Schizophrenia Severity of Illness&#xD;
             (CGI-SCH-S) overall severity score ≤4 at Screening Visit 1.&#xD;
&#xD;
          -  The patient does not currently have a diagnosis of Major Depressive Disorder or have&#xD;
             depressive symptoms rated with a total score ≥5 on the Calgary Depression Scale for&#xD;
             Schizophrenia (CDSS).&#xD;
&#xD;
          -  The patient has no history of violent behaviour for the last 12 months prior to&#xD;
             Screening Visit 1.&#xD;
&#xD;
          -  The patient has a caregiver or an identified responsible person (for example, partner,&#xD;
             family member, social worker, case worker, or nurse) considered reliable by the&#xD;
             investigator in providing support to the patient to ensure compliance with study&#xD;
             treatment, outpatient visits, and protocol procedures.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  The patient has had an acute exacerbation requiring hospitalization within the last 6&#xD;
             months prior to Screening Visit 1.&#xD;
&#xD;
          -  The patient has had an acute exacerbation requiring change in antipsychotic medication&#xD;
             (with reference to drug or dose) within the last 6 months prior to Screening Visit 1.&#xD;
&#xD;
          -  The patient has a current diagnosis or a history of substance use disorder according&#xD;
             to DSM-5® criteria within 6 months prior to Screening Visit 1 with the exception of&#xD;
             tobacco, or mild cannabis or mild alcohol use disorder (occasional - but not weekly&#xD;
             recreational cannabis use is acceptable). Patients with a positive drug screen test&#xD;
             for opiates, methadone, cocaine, amphetamines [including ecstasy], barbiturates,&#xD;
             verified by repeated testing, are excluded from the study.&#xD;
&#xD;
          -  The patient is at significant risk of harming himself/herself or others in the&#xD;
             investigator's opinion.&#xD;
&#xD;
          -  The patient has tested positive for hepatitis A virus antibody (anti-HAV IgM),&#xD;
             hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (anti-HCV). If the&#xD;
             anti-HCV test result is positive, but acute/chronic infection is excluded with a&#xD;
             negative HCV RNA test patient can be included in the study.&#xD;
&#xD;
          -  The patient has tested positive for human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  The patient has a present condition that might compromise liver function (for example,&#xD;
             alcohol abuse, hepatitis, hepatic insufficiency, cholestasis, haemachromatosis,&#xD;
             deficit in alpha 1 antitrypsine, Wilson's Disease, autoimmune diseases, cirrhosis).&#xD;
&#xD;
          -  The patient has any other disorder for which the treatment takes priority over&#xD;
             treatment of schizophrenia or is likely to interfere with the study treatment or&#xD;
             impair treatment compliance.&#xD;
&#xD;
        Other in- and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mental Health Center Prof. Dr. Ivan Temkov EOOD (BG0001)</name>
      <address>
        <city>Bourgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Dr. Hristo Stambolski (BG0007)</name>
      <address>
        <city>Kazanlak</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Psychiatric Hospital Lovech (BG0012)</name>
      <address>
        <city>Lovech</city>
        <zip>5500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Department for men with acute mental diseases-NPH Sv. Ivan Rilski (BG0010)</name>
      <address>
        <city>Novi Iskar</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Dr.Georgi Stranski EAD (BG0006)</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.Svetlozar Georgiev MD, Office of Office of Ambulatory for Group Practice for Specialized Psychiartic Help ¿ PHILIPOPOLIS OOD (BG0014)</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Psychiatric Hospital - Sevlievo (BG009)</name>
      <address>
        <city>Sevlievo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center INTERMEDICA (BG0003)</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC Mladost-M (BG0004)</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC Mladost-M Varna OOD (BG0005)</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Centre Medical plus (BG008)</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Mental Health Veliko Tarnovo (BG0013)</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Center-Vratsa EOOD (BG0002)</name>
      <address>
        <city>Vratsa</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.Jan Holan MD, Office of (CZ0003)</name>
      <address>
        <city>Brno</city>
        <zip>61500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meditrine s.r.o. - Psychiatricka Ambulance, Lecebne Centrum (CZ0005)</name>
      <address>
        <city>Havířov</city>
        <zip>73601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinline services s.r.o. (CZ0006)</name>
      <address>
        <city>Hostivice</city>
        <zip>25301</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatrie HK, s.r.o. (CZ0004)</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50009</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A-Shine s.r.o. (CZ0001)</name>
      <address>
        <city>Plzen</city>
        <zip>31200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Neuropsychiatric Care (INEP) (CZ0007)</name>
      <address>
        <city>Praha 8</city>
        <zip>18600</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienthali Kliinik (EE0001)</name>
      <address>
        <city>Tallinn</city>
        <zip>11315</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OU Jaanson &amp; Laane (EE0002)</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Pratice For Neurology/Psychiatry (DE0003)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr.Kirsten Hahn (DE0002)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralinstitut fur Seelische Gesundheit (ZI)-Leitung Abteilung Molekulares Neuroimaging (DE0004)</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Frank Kuehn MD, Office Of (DE001)</name>
      <address>
        <city>Oranienburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Eberhard-Karls-Universitaet Tuebingen (DE0007)</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyiro Gyula Hospital - OPAI (HU0006)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem-Neurologiai Klinika (HU0005)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Hospital (HU0008)</name>
      <address>
        <city>Gyöngyös</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Mathe es Tarsa Bt (HU0001)</name>
      <address>
        <city>Kalocsa</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mor Oktato Korhaz (HU0003)</name>
      <address>
        <city>Kaposvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz, Pszichiatriai es Pszichoterapias Osztaly (HU0002)</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Javorszky Odon Hospital (HU0004)</name>
      <address>
        <city>Vác</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daugavpils Psychoneurological Hospital (LV0005)</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gintermuiza (LV0001)</name>
      <address>
        <city>Jelgava</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jsc Piejuras Slimnica Psychiatry Clinic (LV0003)</name>
      <address>
        <city>Liepāja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga Centre Of Psychiatry And Addiction Disorders (LV0002)</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sigulda Hospital Outpatient Clinic (LV0006)</name>
      <address>
        <city>Sigulda</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski (PL0012)</name>
      <address>
        <city>Bełchatów</city>
        <zip>97400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wlokiennicza Med Specjalistyczna Praktyka Lekarska dr n. med. Tomasz Markowski (PL0005)</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med-Ars (Pl0010)</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia Psychicznego Biomed - Jan Latala (PL0006)</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przychodnia Syntonia Izabela Chojnowska-Cwiakala (PL0011)</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syntonia Sp. z o.o. (PL0002)</name>
      <address>
        <city>Pruszcz Gdański</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Si Inpn Namsu (Ua0003)</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Si Inpn Namsu (Ua0008)</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kherson Regional Psychiatric Hospital (UA0009)</name>
      <address>
        <city>Kherson</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiev Regional Specialized Psycho-Narcological Medical Care (UA0005)</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution Kirovograd Regional Psychiatric Hospital. Donetsk National Medical University, Chair of psychiatry, psychotherapy, narcology and medical psychology (UA0004)</name>
      <address>
        <city>Kropyvnytskyi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Railway Clinical Hospital #1, Ukr Research Institute, Social And Forensic Psychatriy And Drug Abuse (UA0007)</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odessa Regional Medical Centre of Mental Health (UA0006)</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ukrainian Medical Stomatological Academy, Chair Of Psychiatry, Narcology And Medical Psychology Based On O.F. Maltsev Poltava Regional Clinical Psychiatric Hospital (UA0001)</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnitsa National Medical University (UA0002)</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 3, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2019</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03793712
org study id: 17972A
nct id: NCT03793712
lead sponsor: 
is fda regulated drug: No
is fda regulated device: No
A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms
      in patients with schizophrenia
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Double (Participant, Investigator)
measure: Change in Negative Symptom Scale (BNSS) total score
time frame: from baseline to Week 12
description: The BNSS is a brief clinician rating scale, intended to measure negative symptoms. It consists of 13 items organized into 6 subscales: anhedonia, distress, asociality, avolition, blunted affect and alogia. The items score the impairment. Items 1 to 4 are rated from 0 (Normal) to 6 (Extremely severe) and items 5 to 13 are rated from 0 (No impairment) to 6 (Severe deficit). The BNSS total score is calculated by summing the 13 individual items; subscale scores are calculated by summing the individual items within each subscale. Users of the BNSS should have training in psychiatric interview techniques and have clinical experience working with patients with schizophrenia and related psychotic disorders. The BNSS total scores ranges from 0 to 78.
measure: Change in Personal and Social Performance (PSP) score
time frame: from baseline to Week 12
description: The PSP is a clinician-rated scale designed and validated to measure a patient's current level of social functioning. The PSP consists of 4 items: socially useful activities (including work and study), personal and social relationships, self-care, and disturbing and aggressive behaviours. The 4 items are assessed on a 6-point scale, from absent to very severe. Based on these assessments and their combination, individual scores are converted into a global score ranging from 1 to 100.
measure: Change in Positive and Negative Syndrome Scale (PANSS) total score
time frame: from baseline to Week 12
description: The PANSS is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS includes 3 sub-scales and 30 items
measure: Change in PANSS Marder Negative Symptom Factor score: negative symptoms
time frame: from baseline to Week 12
description: The PANSS is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS includes 3 sub-scales and 30 items
measure: Change in PANSS Negative subscale score
time frame: from baseline to Week 12
description: The PANSS is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS includes 3 sub-scales and 30 items
measure: Change in Clinical Global Impression - Schizophrenia (CGI-SCH-S) negative symptoms score
time frame: from baseline to Week 12
description: The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive and depressive) and the overall severity of the disorder. The CGI-SCH-S severity of illness category symptoms and overall severity are rated on a 7-point scale ranging from 1 (normal - not ill) to 7 (Among the most severely ill). For the first four ratings (positive, negative, depressive, and cognitive symptoms), the assessment should focus on the severity of symptoms only. Additionally, for 'overall severity' rating, both severity of symptoms and interference with functioning should be considered.
measure: Clinical Global Impression - Schizophrenia (CGI-SCH-DC) negative symptoms score
time frame: at Week 12
description: The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive and depressive) and the overall severity of the disorder. In the CGI-SCH-DC degree of change category symptoms and overall severity are rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Each single rating (conditions of severity and degree of improvement) and overall ratings of severity and improvement are scored independently and no total score is derived.
measure: CGI-SCH-DC negative symptoms response
time frame: at Week 12
description: The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive and depressive) and the overall severity of the disorder. In the CGI-SCH-DC degree of change category symptoms and overall severity are rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Each single rating (conditions of severity and degree of improvement) and overall ratings of severity and improvement are scored independently and no total score is derived. Response defined as CGI-SCH-DC negative symptoms = 1 or 2
measure: BNSS response
time frame: at Week 12
description: The BNSS is a brief clinician rating scale, intended to measure negative symptoms. It consists of 13 items organized into 6 subscales: anhedonia, distress, asociality, avolition, blunted affect and alogia. The items score the impairment. Items 1 to 4 are rated from 0 (Normal) to 6 (Extremely severe) and items 5 to 13 are rated from 0 (No impairment) to 6 (Severe deficit). The BNSS total score is calculated by summing the 13 individual items; subscale scores are calculated by summing the individual items within each subscale. Users of the BNSS should have training in psychiatric interview techniques and have clinical experience working with patients with schizophrenia and related psychotic disorders. The BNSS total scores ranges from 0 to 78. Response criteria defined as 20,30 or 40% decrease in BNSS total score.
measure: Change in PANSS -Positive subscale score
time frame: from baseline to Week 12
description: The PANSS is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS includes 3 sub-scales and 30 items
measure: Change in Clinical Global Impression - Schizophrenia (CGI-SCH-S) severity of illness overall severity score
time frame: from baseline to Week 12
description: The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive and depressive) and the overall severity of the disorder. The CGI-SCH-S severity of illness category symptoms and overall severity are rated on a 7-point scale ranging from 1 (normal - not ill) to 7 (Among the most severely ill). For the first four ratings (positive, negative, depressive, and cognitive symptoms), the assessment should focus on the severity of symptoms only. Additionally, for 'overall severity' rating, both severity of symptoms and interference with functioning should be considered.
measure: Clinical Global Impression - Schizophrenia (CGI-SCH-DC) degree of change in overall severity score
time frame: at Week 12
description: The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive and depressive) and the overall severity of the disorder. In the CGI-SCH-DC degree of change category symptoms and overall severity are rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Each single rating (conditions of severity and degree of improvement) and overall ratings of severity and improvement are scored independently and no total score is derived.
measure: Change in Calgary Depression Scale for Schizophrenia (CDSS) total score
time frame: from baseline to Week 12
description: The CDSS is a 9-item clinician rated scale specifically developed for the assessment of depression in patients with schizophrenia. The items on the CDSS are all typical depressive symptoms and do not appear to overlap with the negative symptoms of schizophrenia. All items are rated on a 4-point scale from 0 (absent) to 3 (severe)
arm group label: Lu AF11167 low dose
arm group type: Experimental
arm group label: Lu AF11167 high dose
arm group type: Experimental
arm group label: Placebo
arm group type: Placebo Comparator
intervention type: Drug
intervention name: Lu AF11167 (1-2 mg/day)
description: Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
arm group label: Lu AF11167 low dose
intervention type: Drug
intervention name: Lu AF11167 (3-4 mg/day)
description: Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
arm group label: Lu AF11167 high dose
intervention type: Drug
intervention name: Placebo
description: Placebo oral dose, tablets. Once daily. 12 weeks.
arm group label: Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: No
last name: Email contact via H. Lundbeck A/S
role: Study Director
affiliation: LundbeckClinicalTrials@Lundbeck.com
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Bulgaria
country: Czechia
country: Estonia
country: Germany
country: Hungary
country: Latvia
country: Poland
country: Ukraine
responsible party type: Sponsor
mesh term: Schizophrenia
sharing ipd: Undecided